Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938118 | 0.79 | AGXT (0.42) | — | |
| SCHEMBL4933092 | 0.74 | EPHX2 (0.44) | HCRTR1HCRTR2 | |
| SCHEMBL4938625 | 0.73 | HSD17B1 (0.46) | KDR | |
| SCHEMBL4931268 | 0.72 | PRMT6 (0.44) | HSD17B10NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4938110 | 0.70 | IDO1 (0.38) | RAB9A | |
| SCHEMBL20553211 | 0.70 | MAOA (0.39) | — | |
| SCHEMBL4931411 | 0.68 | KDM1A (0.44) | RAB9AGRM1 | |
| SCHEMBL12810197 | 0.67 | SMN1; SMN2 (0.49) | HSD17B10NPC1RAB9ASMN1; SMN2GRM1 | |
| SCHEMBL6196778 | 0.67 | NPC1 (0.56) | HSD17B10PDE10ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4937791 | 0.66 | MAOB (0.46) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | claimed |
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1831170-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | HSD17B10 3231/4885HCRTR1 1945/4885HCRTR2 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.